The CT-based Deep Learning Model Predicts Complications in Partial Nephrectomy
Launched by DU LINGZHI · Mar 12, 2025
Trial Information
Current as of May 09, 2025
Completed
Keywords
ClinConnect Summary
In this study, patients diagnosed with renal cell carcinoma or renal cyst who underwent partial nephrectomy across multiple centers was included. And the participants were excluded if they had (a) missing or unavailable imaging data or (b) no available enhanced CT images. The cohort was divided into training and test sets at a 7:3 ratio. After that, the radiomics features were extracted from the images, and lasso regression was used to select features. Then a deep learning model was developed to predict complications and risk grades and compared with traditional classification models (RENAL...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Clinical diagnosis of renal cell carcinoma or renal cyst
- • Underwent partial nephrectomy between June 2014 and July 2024
- Exclusion Criteria:
- • Missing or unavailable imaging data
- • No available enhanced CT images
About Du Lingzhi
Du Lingzhi is a pioneering clinical trial sponsor dedicated to advancing healthcare through innovative research and development. With a strong focus on harnessing the potential of natural compounds and traditional medicine, Du Lingzhi conducts rigorous clinical trials to evaluate the efficacy and safety of its therapeutic products. Committed to scientific excellence and ethical standards, the organization collaborates with leading researchers and institutions to foster advancements in medical science, ultimately aiming to improve patient outcomes and enhance quality of life.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Shanghai, Xuhui District, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported